Medtronic, Inc. MDT today announced CE
(Conformité Européenne) Mark approval of its innovative Sentrino® Continuous
Glucose Management System, the first minimally invasive continuous glucose
monitoring (CGM) system specifically designed for use in hospital critical
care units (CCU). The Sentrino CGM System provides real-time trend data that
serves as an early warning system, allowing clinicians to appropriately
intervene to prevent glycemic excursions and maximize the patient's time in
the target range. In addition, the system integrates simply into the clinical
workflow in the hospital to improve the quality and efficiency of maintaining
glucose control.
Improved glucose management in critical care patients may reduce morbidity,
mortality and the length of stay.^1-3 While glucose control is a standard
practice for diabetic and non-diabetic patients in the CCU, it's difficult to
achieve. The Sentrino CGM System and the trending data it provides help
optimize glucose management practices. Sentrino is an investigational device
only in the US and not approved for sale in the US.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in